Updating on my last note, in this post I will look at Illumina and Grail's prospects for growth in 2025, and beyond. One of the reasons I have suggested in past notes why Illumina was so keen to ...

Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Illumina (ILMN) to $180 from $184 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech ...

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through ...

Year to date, Illumina stock has increased around 8% while underperformed its iShares Core S&P Mid-Cap ETF. To expand its reach in single-cell analysis and multiomics research, Illumina acquired ...

Illumina, Inc. (NASDAQ:ILMN) was removed from the index. Year to date, the stock has increased around 8%, underperforming iShares Core S&P Mid-Cap ETF (NYSE:IJH). The provider of DNA sequencing ...

Baron Global Advantage Fund highlighted stocks like Illumina, Inc. (NASDAQ:ILMN) in the third quarter 2024 investor letter.

Illumina is an applied genomics technology company that was founded in 1998 with the mission statement: ‘To improve human health by unlocking the power of the genome’. Over the past two ...

BusinessWire India Bengaluru (Karnataka) [India], December 6: Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today celebrated the opening of a global ...